Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited has reported promising results from a sophisticated preclinical study of its CRO-67 drug, which demonstrated significant reductions in both pancreatic tumour volume and barrier cell count, as well as a notable decrease in metastatic spread. These outcomes suggest that CRO-67 could be an innovative and effective treatment for pancreatic cancer, a disease notoriously challenging due to protective barrier cells. The study, conducted in collaboration with UNSW Sydney, supports the potential for further research and development of this dual-cell therapy approach.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.
